Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult... (EU)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also approved (1)
EU
  • Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure. HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment start. The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis.
Product first approved 2009EMA
Featured evidence outside this drug's tracked markets:ZEUS (NCT01856413) · Chronic Hepatitis B · Phase 3 · completed · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT01856413 · Biotest
2012-12 – 2014-09 · Hepatitis B
What this study did
Phase 2 (1)
Other / comorbidity
NCT05345990 · Hannover Medical School
2022-08-15 – 2025-07-31 · Chronic Hepatitis B
What this study did
Phase 1 (1)
Other / comorbidity
NCT03899142 · Prothya Biosolutions
2019-03-20 – 2019-07-04 · Healthy
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT05293158 · Medical University of Graz
2024-11 – 2026-06 · Hepatocellular Carcinoma, HBV
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.